MedMira Inc
XTSX:MIR

Watchlist Manager
MedMira Inc Logo
MedMira Inc
XTSX:MIR
Watchlist
Price: 0.08 CAD 6.67% Market Closed
Market Cap: 57.7m CAD
Have any thoughts about
MedMira Inc?
Write Note

MedMira Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MedMira Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
MedMira Inc
XTSX:MIR
Cash from Financing Activities
CA$5.3m
CAGR 3-Years
N/A
CAGR 5-Years
50%
CAGR 10-Years
1%
Titan Medical Inc
TSX:TMD
Cash from Financing Activities
-$580k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Profound Medical Corp
TSX:PRN
Cash from Financing Activities
$19m
CAGR 3-Years
-29%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Cash from Financing Activities
CA$10.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
18%
Nanalysis Scientific Corp
XTSX:NSCI
Cash from Financing Activities
CA$14.5m
CAGR 3-Years
125%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Cash from Financing Activities
CA$3.4m
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
-5%
No Stocks Found

MedMira Inc
Glance View

Market Cap
56.1m CAD
Industry
Health Care

MedMira, Inc. is a biotechnology company, which through its subsidiaries, engages in the research, development, manufacture, and commercialization of diagnostics and technology platforms. The company is headquartered in Halifax, Nova Scotia. The firm is engaged in the development and commercialization of rapid diagnostics and technology platforms. The MedMira Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its technology platform detects multiple biomarkers specific to several diseases using a single cartridge. Its Multiplo line of rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis uses the platforms capabilities to deliver approximately up to four test results using one test cartridge and one drop of specimen. The company also has a research product line that facilitates technology licensing, contract manufacturing, and regulatory consulting. The firm sells its rapid tests through a network of medical distributors and strategic business development partners to customers in all sectors of the healthcare industry, including laboratories, hospitals and point-of-care clinics, among others.

MIR Intrinsic Value
0.002 CAD
Overvaluation 97%
Intrinsic Value
Price

See Also

What is MedMira Inc's Cash from Financing Activities?
Cash from Financing Activities
5.3m CAD

Based on the financial report for Apr 30, 2024, MedMira Inc's Cash from Financing Activities amounts to 5.3m CAD.

What is MedMira Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
1%

Over the last year, the Cash from Financing Activities growth was 839%.

Back to Top